CELU News and Press, Celularity Inc.

2026-03-10 08:45:12 ET More on Celularity Seeking Alpha’s Quant Rating on Celularity Financial information for Celularity Read the full article on Seeking Alpha For further details see: Celularity secures strategic license deal worth up to $35M for...

Transaction expected to approximately triple NEXGEL’s annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing Licensing and acquiring a diversified suite of 6 established regenerative biomaterial products, most with existing insurance...

Transaction expected to generate up to $35 million in upfront and milestone payments Celularity retains exclusive manufacturing rights, creating continued biomaterials revenue and margin opportunity Organizational realignment reduces operating expenses and sharpens focus on longevity therapeuti...

FLORHAM PARK, N.J., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, today announced receipt of $12.2 Million in net cash proceeds from the sale of approximately $126.3 Million of its unu...

2025-12-26 10:41:52 ET More on Organogenesis Holdings, MiMedx Group Organogenesis: High-Tech Skin Substitute Company On Sale Organogenesis Holdings Inc. (ORGO) Q3 2025 Earnings Call Transcript MiMedx: Breakout Setup Into A Policy Overhaul Organogenesis starts...

2025-12-26 11:09:21 ET More on Organogenesis Holdings, MiMedx Group Organogenesis: High-Tech Skin Substitute Company On Sale Organogenesis Holdings Inc. (ORGO) Q3 2025 Earnings Call Transcript MiMedx: Breakout Setup Into A Policy Overhaul Organogenesis starts...

FLORHAM PARK, N.J., Dec. 26, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today released comments by Robert J. Hariri, M.D., Ph.D., CEO and Chairman, on the Cent...

FLORHAM PARK, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today announced the closing of its previously disclosed financing transactions with Phi...

The contemplated financing transactions would provide up to $12 Million in capital to support Celularity’s strategic priorities around longevity and preservation of human performance. FLORHAM PARK, N.J., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celular...

FLORHAM PARK, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, announced today a strategic partnership with DefEYE, Inc. (“DefEYE”), a n...